About: http://data.cimple.eu/news-article/c07829cb621cdffbaccf803815645c8eae03d300df1b30d1a9f71145     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • UK pharmaceuticals group AstraZeneca said on Monday it will advance trials of a Covid-19 treatment to a crucial third stage, after the United States invested $486 million (411 million euros) in its development. The US government's investment will see up to 100,000 doses delivered "towards the end of 2020", with the option for another one million doses next year, AstraZeneca said. The company is enrolling 6,100 participants in two separate testing regimes of the "long-acting antibody (LAAB)" combination treatment in the United States and other countries, starting "in the next weeks". One will evaluate its safety and efficacy "to prevent infection for up to 12 months" and involves around 5,000 participants, the company said in a statement to the London Stock Exchange. The second will evaluate post-exposure prophylaxis and pre-emptive treatment in approximately 1,100 participants, it added. AstraZeneca said it is also planning additional trials to evaluate the drug in approximately 4,000 patients for the treatment of Covid-19. "This agreement with the US government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating COVID-19 infections," chief executive Pascal Soriot said. jj/ar/txw
schema:headline
  • US funding sees Covid-19 antibody trial enter next phase
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software